{"public_id":"co_ea84fcf6f4562463961667d7f2494f2f","status":"active","merged_into_public_id":null,"resolved_public_id":"co_ea84fcf6f4562463961667d7f2494f2f","name":"azathioprine","description":"An immunosuppressive drug suggested as a first-line treatment for neuromyelitis optica.","aliases":[],"types":["drug"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":1215691,"title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)","citation_count":568,"url":"https://sah.borca.ai/papers/1215691"}],"claims":[{"public_id":"cl_7e0d7e49fba033332de51522b57b39ee","text":"Early initiation of therapy is recommended, with azathioprine and rituximab suggested as first-line treatments and methotrexate, mycophenolate mofetil, and mitoxantrone recommended as second-line treatments.","corpus_id":1215691,"url":"https://sah.borca.ai/claims/cl_7e0d7e49fba033332de51522b57b39ee"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_ea84fcf6f4562463961667d7f2494f2f","url":"https://sah.borca.ai/concepts/co_ea84fcf6f4562463961667d7f2494f2f"}